sb-lina
Generic Name
Linagliptin 5 mg Tablet
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| sb lina 5 mg tablet | ৳ 15.00 | N/A |
Description
Overview of the medicine
Linagliptin is an oral anti-diabetic medicine used to improve blood sugar control in adults with type 2 diabetes mellitus. It works by increasing the levels of natural substances called incretins, which help control blood sugar.
Uses & Indications
Dosage
Adults
The recommended dose is 5 mg once daily, taken orally with or without food.
Elderly
No dose adjustment is required in elderly patients.
Renal_impairment
No dose adjustment is required for patients with renal impairment, including those on dialysis, due to its primary non-renal elimination.
How to Take
Take the tablet orally once daily with or without food. Swallow the tablet whole with water.
Mechanism of Action
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by selectively inhibiting the enzyme DPP-4. This inhibition leads to an increase in the levels of active incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones enhance glucose-dependent insulin secretion from pancreatic beta cells and reduce glucagon secretion from pancreatic alpha cells, thereby lowering blood glucose levels.
Pharmacokinetics
Onset
Glucose-lowering effects typically observed within a few hours of administration.
Excretion
Primarily eliminated via the enterohepatic route (80% feces) and approximately 5% renally. Renal excretion is low and largely unchanged by renal impairment.
Half life
The terminal half-life is long (~131 hours) due to saturable binding to DPP-4, but the effective half-life for DPP-4 inhibition that allows for once-daily dosing is about 24 hours.
Absorption
Rapidly absorbed after oral administration, peak plasma concentrations typically reached within 1.5 hours. Absolute bioavailability is approximately 30%.
Metabolism
Minimally metabolized; the primary metabolic pathway involves hydrolysis of the piperidine ring, but most of the drug is excreted unchanged.
Side Effects
Contraindications
- Hypersensitivity to linagliptin or any of the excipients of the tablet.
Drug Interactions
Rifampicin
Coadministration with rifampicin, a strong P-glycoprotein (P-gp) and CYP3A4 inducer, significantly decreases linagliptin exposure, potentially reducing its efficacy. Concurrent use is not recommended.
Other anti-diabetic agents
Increased risk of hypoglycemia when coadministered with sulfonylureas or insulin. Dose adjustment of sulfonylurea or insulin may be required.
Storage
Store below 30°C in a dry place, away from direct light and moisture. Keep out of reach of children.
Overdose
In the event of an overdose, symptomatic treatment is recommended. Linagliptin is unlikely to be removed by hemodialysis or peritoneal dialysis.
Pregnancy & Lactation
Pregnancy Category B. Limited data on use in pregnant women; use only if clearly needed and the potential benefit outweighs the potential risk to the fetus. It is not known if linagliptin is excreted in human milk; caution should be exercised when administered to a nursing woman.
Side Effects
Contraindications
- Hypersensitivity to linagliptin or any of the excipients of the tablet.
Drug Interactions
Rifampicin
Coadministration with rifampicin, a strong P-glycoprotein (P-gp) and CYP3A4 inducer, significantly decreases linagliptin exposure, potentially reducing its efficacy. Concurrent use is not recommended.
Other anti-diabetic agents
Increased risk of hypoglycemia when coadministered with sulfonylureas or insulin. Dose adjustment of sulfonylurea or insulin may be required.
Storage
Store below 30°C in a dry place, away from direct light and moisture. Keep out of reach of children.
Overdose
In the event of an overdose, symptomatic treatment is recommended. Linagliptin is unlikely to be removed by hemodialysis or peritoneal dialysis.
Pregnancy & Lactation
Pregnancy Category B. Limited data on use in pregnant women; use only if clearly needed and the potential benefit outweighs the potential risk to the fetus. It is not known if linagliptin is excreted in human milk; caution should be exercised when administered to a nursing woman.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
2-3 years from the date of manufacture, specific to lot.
Availability
Available in pharmacies and hospitals
Approval Status
Approved by major regulatory bodies (e.g., FDA, EMA, DGDA)
Patent Status
Patent protected for originator, generics available
Clinical Trials
Linagliptin has undergone extensive clinical trials demonstrating its efficacy and safety in improving glycemic control in type 2 diabetes, both as monotherapy and in combination with other anti-diabetic agents. Cardiovascular outcome trials (e.g., CAROLINA, CARMELINA) have shown cardiovascular safety.
Lab Monitoring
- Hemoglobin A1c (HbA1c) levels regularly to assess glycemic control.
- Renal function (eGFR) should be monitored periodically, though dose adjustment is not required.
- Liver function tests (LFTs) periodically.
Doctor Notes
- Linagliptin is a good option for type 2 diabetes patients, especially those with renal impairment, as it does not require dose adjustment based on kidney function.
- Counsel patients on potential risk of hypoglycemia when combined with sulfonylureas or insulin.
- Advise patients to report any symptoms of pancreatitis (e.g., severe abdominal pain) or bullous pemphigoid (e.g., skin blistering).
Patient Guidelines
- Take this medicine exactly as prescribed by your doctor.
- Do not stop taking the medicine without consulting your doctor, even if you feel better.
- Regularly monitor your blood sugar levels as advised by your healthcare provider.
- Combine with a healthy diet and regular exercise for best results.
Missed Dose Advice
If a dose is missed, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
This medicine is not expected to affect your ability to drive or operate machinery directly. However, if used in combination with other anti-diabetic agents like sulfonylureas or insulin, there is a risk of hypoglycemia which can impair driving ability. Be aware of symptoms of hypoglycemia.
Lifestyle Advice
- Maintain a balanced diet low in sugar and saturated fats.
- Engage in regular physical activity (e.g., walking, cycling) for at least 30 minutes most days of the week.
- Maintain a healthy weight.
- Avoid excessive alcohol consumption.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.